60 Binney Street
Cambridge, MA 02142
United States
617 675 7270
https://www.2seventybio.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 274
Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
---|---|---|---|---|
Mr. William D. Baird III, M.B.A. | CEO, President & Director | 708k | N/D | 1972 |
Ms. Victoria Eatwell | Chief Financial Officer | N/D | N/D | 1986 |
Ms. Jessica Snow | Senior VP of Quality and Head of Operations | N/D | N/D | 1979 |
Anna Truppel-Hartmann | Chief Medical Officer | N/D | N/D | N/D |
2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company's products pipeline includes Abecma, a chimeric antigen receptor T-cell product candidates for the treatment of multiple myeloma. It has a collaboration arrangement with Bristol Myers Squibb Company. The company was incorporated in 2021 and is headquartered in Cambridge, Massachusetts.
La calificación ISS Governance QuickScore de 2seventy bio, Inc. a partir del 1 de mayo de 2024 es 9. Las puntuaciones principales son Auditoría: 8; Junta: 8; Derechos del accionista: 8; Compensación: 9.